trending Market Intelligence /marketintelligence/en/news-insights/trending/eya3ejbrorvbsq3spbrq4g2 content esgSubNav
In This List

Advaxis seeks to raise $20M from common stock, warrants offering

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Advaxis seeks to raise $20M from common stock, warrants offering

Advaxis Inc. expects to raise gross proceeds of about $20 million from its underwritten public offering of 16,666,666 common shares and warrants to purchase 14,166,666 shares.

Each common share is being sold together in a fixed combination with a warrant to purchase 0.85 common share.

Holders can immediately exercise warrants at $1.50 per share, subject to anti-dilution adjustments. The warrants will expire six years after issuance.

The Princeton, N.J.-based biotechnology company plans to use the funds from the offering for the development of its product pipeline, which includes the experimental cancer treatment ADXS-HOT.

The offering is expected to close Sept. 11, subject to customary closing conditions.

Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. are acting as joint book-running managers for the offering.